Heliyon (Oct 2021)
PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2
- Saumyabrata Mazumder,
- Ruchir Rastogi,
- Avinash Undale,
- Kajal Arora,
- Nupur Mehrotra Arora,
- Biswa Pratim,
- Dilip Kumar,
- Abyson Joseph,
- Bhupesh Mali,
- Vidya Bhushan Arya,
- Sriganesh Kalyanaraman,
- Abhishek Mukherjee,
- Aditi Gupta,
- Swaroop Potdar,
- Sourav Singha Roy,
- Deepak Parashar,
- Jeny Paliwal,
- Sudhir Kumar Singh,
- Aelia Naqvi,
- Apoorva Srivastava,
- Manglesh Kumar Singh,
- Devanand Kumar,
- Sarthi Bansal,
- Satabdi Rautray,
- Manish Saini,
- Kshipra Jain,
- Reeshu Gupta,
- Prabuddha Kumar Kundu
Affiliations
- Saumyabrata Mazumder
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Ruchir Rastogi
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Avinash Undale
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Kajal Arora
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Nupur Mehrotra Arora
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Biswa Pratim
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Dilip Kumar
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Abyson Joseph
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Bhupesh Mali
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Vidya Bhushan Arya
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Sriganesh Kalyanaraman
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Abhishek Mukherjee
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Aditi Gupta
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Swaroop Potdar
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Sourav Singha Roy
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Deepak Parashar
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Jeny Paliwal
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Sudhir Kumar Singh
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Aelia Naqvi
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Apoorva Srivastava
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Manglesh Kumar Singh
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Devanand Kumar
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Sarthi Bansal
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Satabdi Rautray
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Manish Saini
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Kshipra Jain
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Reeshu Gupta
- Premas Biotech Private Limited, Manesar, Gurugram, India
- Prabuddha Kumar Kundu
- Corresponding author.; Premas Biotech Private Limited, Manesar, Gurugram, India
- Journal volume & issue
-
Vol. 7,
no. 10
p. e08124
Abstract
The rapid development of safe and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is a necessary response to coronavirus outbreak. Here, we developed PRAK-03202, the world's first triple antigen virus-like particle vaccine candidate, by cloning and transforming SARS-CoV-2 gene segments into a highly characterized S. cerevisiae-based D-Crypt™ platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunization using three different doses of PRAK-03202 induced an antigen-specific (spike, envelope, and membrane proteins) humoral response and neutralizing potential. Peripheral blood mononuclear cells from convalescent patients showed lymphocyte proliferation and elevated interferon levels suggestive of epitope conservation and induction of T helper 1-biased cellular immune response when exposed to PRAK-03202. These data support further clinical development and testing of PRAK-03202 for use in humans.
